The observation that JNK1 and JNK2 promote obesity (by inhibiting energy expenditure) and cause insulin resistance in peripheral tissues indicates that drugs that block JNK signaling may be therapeutically beneficial for the treatment of pre-diabetes (Sabio and Davis, 2010). The gene discussed is MAPK9; the disease is obesity due to melanocortin 4 receptor deficiency.